戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ia secondary to therapy with drugs targeting DNA topoisomerase II.
2  specifying functional doxorubicin-resistant DNA topoisomerase II.
3  for their inhibitory activity against human DNA topoisomerase II.
4 nd compound 11 was an in vitro, inhibitor of DNA topoisomerase II.
5 d related to their ability to interfere with DNA topoisomerase II.
6 topopyrones A-D also act as poisons of human DNA topoisomerase II.
7 nism of substrate recognition and binding by DNA topoisomerase II.
8 ATP-modulated formation of contacts in yeast DNA topoisomerase II.
9 een the NH2- and COOH-terminal half of yeast DNA topoisomerase II.
10 sion of DNA topoisomerase IIbeta, one of two DNA topoisomerase II activities known to exist in mammal
11                                     The only DNA topoisomerase II activity conclusively demonstrated
12         Despite the likely requirement for a DNA topoisomerase II activity during synthesis of mitoch
13 ent study, we report the discovery of a type DNA topoisomerase II activity in bovine mitochondria.
14         The effect of these substitutions on DNA topoisomerase II activity is not known.
15           Alternatives include inhibition of DNA topoisomerase II activity, regulation of cell cycle
16 anticancer drugs are known to interfere with DNA topoisomerase II activity.
17 ealed that the 3F3/2 antibody binds to human DNA topoisomerase II alpha (HsTIIalpha) from mitotic but
18  from LLC-Pk was created in which endogenous DNA topoisomerase II alpha (topoII alpha) protein was do
19  we have characterized the recombinant human DNA topoisomerase II alpha containing either single or d
20                                              DNA topoisomerase II-an essential nuclear enzyme in DNA
21 an emerging ATPase superfamily that includes DNA topoisomerase II and Hsp90.
22                        Footprinting of yeast DNA topoisomerase II and its NH2- and COOH-terminal trun
23 ized and evaluated for their effects against DNA topoisomerase II and KB or 1-resistant KB-7d tumor c
24 n synthesized and evaluated as inhibitors of DNA topoisomerase II and tumor cell growth in tissue cul
25 rren protein may function as an activator of DNA topoisomerase II and/or as a component of the Xenopu
26 have been screened for their potency against DNA topoisomerase II, and it has been observed that both
27                                   The enzyme DNA topoisomerase II associates with gene promoter regio
28                                        Human DNA topoisomerase II binding protein 1 (TopBP1) contains
29      These mutant forms also fail to recruit DNA topoisomerase II binding protein 1 (TOPBP1), suppres
30 by deacetylating the ATR-interacting protein DNA topoisomerase II binding protein 1 (TOPBP1), thereby
31  by ETAA1 activator of ATR kinase (ETAA1) or DNA topoisomerase II binding protein 1 (TOPBP1).
32  mediator of DNA damage checkpoint 1 (MDC1), DNA topoisomerase II-binding protein 1 (TOPBP1) and cell
33                                    The human DNA topoisomerase II-binding protein 1 (TopBP1) protein
34 by which merbarone, a catalytic inhibitor of DNA topoisomerase II, can block tumor cell growth withou
35                                              DNA topoisomerase II catalyzes two different chemical re
36                                 Induction of DNA topoisomerase II cleavage complexes in CEM and K562
37 oside and both etoposide metabolites induced DNA topoisomerase II cleavage complexes in the hematopoi
38 ransfer; however, consistent with reciprocal DNA topoisomerase II cleavage events in MLL and AF-4 in
39 etoposide, but also its metabolites, enhance DNA topoisomerase II cleavage near MLL translocation bre
40  The MLL genomic breakpoint was a functional DNA topoisomerase II cleavage site in an in vitro assay.
41 anslocation breakpoints in MLL and AF-4 were DNA topoisomerase II cleavage sites.
42 toposide metabolite- and doxorubicin-induced DNA topoisomerase II cleavage was examined in normal hom
43 ibitor-related leukemias is a consequence of DNA topoisomerase II cleavage.
44                                              DNA topoisomerase II completely removes DNA intertwining
45           However, doxorubicin also binds to DNA topoisomerase II, converting the enzyme into a DNA d
46                                          The DNA topoisomerase II copurifies with mitochondria and di
47 mal breakage resulting from stabilization of DNA topoisomerase II covalent complexes by epipodophyllo
48               Repair of etoposide-stabilized DNA topoisomerase II covalent complexes may initiate MLL
49 amage the MLL breakpoint cluster region in a DNA topoisomerase II-dependent manner like the parent dr
50 F-beta activated kinase (TAK)1, TAB1, c-FOS, DNA topoisomerase II, DNA polymerase alpha, dihydrofolat
51 e phosphosites evolved from acidic residues (DNA topoisomerase II, enolase, and C-Raf) show that the
52 ontaining 100 mM NaCl, in which intact yeast DNA topoisomerase II exhibits robust DNA-dependent ATPas
53 ating that purified Saccharomyces cerevisiae DNA topoisomerase II exists as a stable dimer in solutio
54       In the preceding paper, we showed that DNA topoisomerase II from Saccharomyces cerevisiae binds
55                                When bound to DNA, topoisomerase II from Saccharomyces cerevisiae exhi
56 de links across one dimer interface of yeast DNA topoisomerase II have confirmed this mechanism.
57 (eg, O6-methylguanine-DNA methyltransferase, DNA topoisomerase II, hMLH1, p21WAF1/CIP1; 4) activation
58 TA-3' sequences were reciprocally cleaved by DNA topoisomerase II in the presence of etoposide, etopo
59  does not serve as an essential activator of DNA topoisomerase II in vivo.
60 processing of the staggered nicks induced by DNA topoisomerase II, including exonucleolytic deletion
61 derivatives (11-23) were designed to enhance DNA topoisomerase II inhibition, overcome drug resistanc
62 F/SF and then exposed to Adriamycin (ADR), a DNA topoisomerase II inhibitor, exhibit an altered patte
63        DNA lesions generated by etoposide, a DNA topoisomerase II inhibitor, or by exonuclease treatm
64                Few t(9;11) translocations in DNA topoisomerase II inhibitor-related leukemias have be
65 al breakage leading to MLL translocations in DNA topoisomerase II inhibitor-related leukemias is a co
66 gesting that the bisdioxopiperazine class of DNA topoisomerase II inhibitors directly interacts with
67  24, and 25 were "cleavable-complex"-forming DNA topoisomerase II inhibitors with either improved or
68       Prior therapy in this patient included DNA topoisomerase II inhibitors, alkylating agents, and
69 s, were treated with various combinations of DNA topoisomerase II inhibitors, alkylating agents, or i
70 d alkylating agents, DNA topoisomerase I and DNA topoisomerase II inhibitors, and local radiation.
71 synthesis and biological evaluation of novel DNA topoisomerase II inhibitors, podophenazine (8), 2'',
72                   Prior therapy included the DNA topoisomerase II inhibitors, teniposide and doxorubi
73 icancer treatment at low cumulative doses of DNA topoisomerase II inhibitors.
74 omplication of primary cancer treatment with DNA topoisomerase II inhibitors.
75 id leukemia who previously were treated with DNA topoisomerase II inhibitors.
76 igation of exposure to natural and synthetic DNA topoisomerase II inhibitors.
77                                              DNA topoisomerase II is a homodimeric molecular machine
78                                              DNA topoisomerase II is a molecular machine that couples
79                                        Human DNA topoisomerase II is an important target in anticance
80                                              DNA topoisomerase II is the target of a variety of impor
81                                              DNA topoisomerase II modulates DNA topology by relieving
82 ty-two IIV-3 genes, including those encoding DNA topoisomerase II, NAD-dependent DNA ligase, SF1 heli
83                                          The DNA topoisomerase II poison and DNA damaging agent, etop
84 y a molar excess of Saccharomyces cerevisiae DNA topoisomerase II produces more negative-noded than p
85 n these results in the context of the entire DNA topoisomerase II reaction cycle are discussed.
86 omosomal recombination by simple exchange of DNA topoisomerase II subunits and DNA-strand transfer; h
87 alidation as biomarkers of responsiveness to DNA topoisomerase II-targeted therapy.
88 t with a model in which binding of an intact DNA topoisomerase II to DNA places the various subfragme
89 enite-induced apoptosis was shown to involve DNA topoisomerase II (Top II) as selenite-induced apopto
90 sformed cells involves thiol modification of DNA topoisomerase II (Top2) based on the following obser
91             The breakage/reunion reaction of DNA topoisomerase II (TOP2) can be interrupted by DNA in
92                                              DNA topoisomerase II (TOP2) cleavable complexes represen
93                                              DNA topoisomerase II (TOP2) enzymes achieve this by bind
94     Our results showed that knockdown of the DNA topoisomerase II (Top2) gene can specifically modula
95                                              DNA topoisomerase II (Top2) is an essential nuclear enzy
96                                              DNA topoisomerase II (TOP2) is required for the unwindin
97                                              DNA topoisomerase II (Top2) is the target of some of the
98                                              DNA topoisomerase II (TOP2) plays a pivotal role in fait
99 ction as a DUB inhibitor, PR-619 is a potent DNA topoisomerase II (TOP2) poison, inducing both DNA to
100 er show that the therapeutic cytotoxicity of DNA topoisomerase II (TOP2) poisons can be enhanced thro
101                                              DNA topoisomerase II (TOP2) poisons induce protein-DNA c
102 formed during replication are decatenated by DNA topoisomerase II (TOP2), and this process is activel
103                            Drugs that target DNA topoisomerase II (Top2), including etoposide (VP-16)
104 ts is reversible and shown to be mediated by DNA topoisomerase II (TOP2).
105 ential targets have been proposed, including DNA topoisomerases II (Top2).
106 atch repair pathway, whereas another for the DNA topoisomerase II (TOP2A) poison etoposide identified
107 , 9, 12, and 13) were shown to inhibit human DNA topoisomerase II (topo II) activity at 5 microM.
108  extrusion by condensins and decatenation by DNA topoisomerase II (topo II) are thought to drive mito
109                      This study reports that DNA topoisomerase II (Topo II) inhibitors, doxorubicin a
110                                              DNA topoisomerase II (topo II) is a target for many clin
111                                              DNA topoisomerase II (topo II) is an essential nuclear e
112 ment with drugs that inhibit the function of DNA topoisomerase II (topo II) is being recognized with
113 py ALL (t-ALL) resulting from treatment with DNA topoisomerase II (topo II) targeting drugs.
114 drug that inhibits the catalytic activity of DNA topoisomerase II (topo II) without damaging DNA or s
115 ry, and one of the clones identified encoded DNA topoisomerase II (Topo II), an enzyme known to have
116 ffects in part via a catalytic inhibition of DNA topoisomerase II (topo II)alpha.
117 se ligands (2-5) were shown to inhibit human DNA topoisomerase-II (TOPO-II) activity at 10 microM.
118                                              DNA topoisomerase II uses a complex, sequential mechanis
119     A covalently cross-linked dimer of yeast DNA topoisomerase II was created by fusing the enzyme wi
120 lypeptide, the resulting heterodimeric yeast DNA topoisomerase II was found to nick plasmid DNA.
121 sis by two NH(2)-terminal fragments of yeast DNA topoisomerase II was studied in the absence and pres
122                                Assuming that DNA topoisomerase II was the mediator of the breakage, p
123       Cysteine-substitution mutants of yeast DNA topoisomerase II were used to test footprinting of t
124 residues within the C-terminal half of yeast DNA topoisomerase II, which corresponds to the A subunit
125                             Studies of yeast DNA topoisomerase II with various alanine-substitution m

 
Page Top